These data imply that downregulation of a Tyrobp network in the presence of a proteinopathy can be beneficial even if not pathologically elevated, regardless of baseline levels and MSN transcriptional dysregulation. The gene discussed is TYROBP; the disease is proteostasis deficiencies.